Abstract: Embodiments of the present disclosure include compositions and methods for treating type 2 diabetes using anti-diabetic steroidal lactones of Withania Coagulans, such as Coagulansin A and derivatives and analogues thereof are described. For example, a method of treating type 2 diabetes in a subject in need thereof, the method comprising administering a therapeutically effective amount of Coagulansin A or a derivative or analogue thereof to the subject is provided. Further described embodiments include compositions and methods of treating muscle atrophy in a subject with type 2 diabetes by initiating regeneration of diseased skeletal muscle myoblasts using anti-diabetic steroidal lactones of Withania Coagulans.

Abstract: Embodiments of the present disclosure include compositions and methods for treating type 2 diabetes using anti-diabetic steroidal lactones of Withania Coagulans, such as Coagulansin A and derivatives and analogues thereof are described. For example, a method of treating type 2 diabetes in a subject in need thereof, the method comprising administering a therapeutically effective amount of Coagulansin A or a derivative or analogue thereof to the subject is provided. Further described embodiments include compositions and methods of treating muscle atrophy in a subject with type 2 diabetes by initiating regeneration of diseased skeletal muscle myoblasts using anti-diabetic steroidal lactones of Withania Coagulans.